Hopantenic acid (homopantothenic acid) is a central nervous system depressant. Formulated as the calcium salt, it is used as a pharmaceutical drug in the Russian Federation under the brand name Pantogam. In Russia it is widely used to treat a variety of neurological, psychological and psychiatric conditions. The drug has been on the pharmaceutical market since 1979 and has been proven to be safe even for children from 3 years old upwards. Hopantenic acid is a natural forming substance, has some of the lowest side effects and considered to be very safe. Use Pantogam to treat a wide variety of cognitive and nervous system disorders with combined sedative and mild stimulant effect. Hopantenic acid is not approved for use in Europe or the United States. GABA receptor agonist.

Tulobuterol is a long-acting beta2-adrenergic receptor agonist. Tulobuterol has almost no effects on blood pressure and heart rate and is highly selective for the tracheal muscle. It is indicated to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, bronchitis, chronic obstructive pulmonary disease (COPD) and emphysema. Serious side effects detected were: tremor, palpitations and serum potassium level decrease.

Diquafosol, a dinucleotide Up4U, is an agonist for purinergic P2Y2 receptor. Diquafosol stimulated water and mucin secretion by acting on P2Y2 receptors on the conjunctival epithelial and goblet cell membrane and elevating intracellular calcium ion concentrations. The Japanese Ministry of Health, Labour and Welfare granted approval for DIQUAS Ophthalmic Solution 3% (diquafosol tetrasodium) for the treatment of dry eye.

Nomegestrol acetate (NOMAC) is a 19-norprogesterone derivative with high biological activity at the progesterone receptor, a weak anti-androgenic effect, but with no binding to estrogen, glucocorticoid or mineralocorticoid receptors. Nomegestrol has been developed by the Monaco-based company Théramex SAM (a Teva subsidiary). Nomegestrol acetate has been used successfully for the treatment of some gynaecological disorders (menstrual disturbances, dysmenorrhoea, premenstrual syndrome) and as a component of hormone replacement therapy in combination with estradiol for the relief of menopausal symptoms; it has been approved in Europe as monotherapy for the treatment of the menopausal syndrome, uterine diseases and menorrhagia, and in combination with an estrogen for the treatment of menopausal symptoms. Nomegestrol acetate in combination with estradiol is used as an oral contraceptive.

Carpronium chloride is a hair growth reagent with a vasodilatory action. In vivo studies indicated that carpronium chloride achieved dilatation of vascular smooth muscle in the microcirculation of rats. FUROZIN SOLUTION 5% (active ingredient Carpronium chloride) has local vasodilating effect and hair growth stimulatory effect to improve alopecia and vitiligo. It is usually used for the prevention of hair loss, for hair growth stimulation, and in the treatment of seborrhea sicca and vitiligo vulgaris.

Clobetasone is a corticosteroid used in dermatology, for treating such skin inflammation as seen in eczema, psoriasis and other forms of dermatitis, and ophthalmology. Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis. It is available as clobetasone butyrate under the brand names Eumosone or Eumovate both manufactured by GlaxoSmithKline. Trimovate also contains Oxytetracycline, an antibiotic, and nystatin, an antifungal. Clobetasone butyrate is classed as a moderately potent topical corticosteroid. Clobetasone butyrate relieves the symptoms of a flare-up by reducing inflammation, itching and redness. It is not a cure for the condition, but it will help to relieve the symptoms. Although less potent topical steriods are often preferred for use in children, a short course of clobetasone butyrate may be prescribed for a child with severe eczema on the arms or legs. Short courses of clobetasone butyrate may also be prescribed for the treatment of psoriasis for areas such as the face, or the inside of elbows and behind the knees. In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome.

Oxabolone is a synthetic anabolic steroid. It can be formulated as the cipionate ester prodrug oxabolone cipionate. Oxabolone cypionate is a structural derivative of nandrolone. It differs via the additional 4-hydroxyl group that is attached, therefore making oxabolone cypionate 4-hydroxynandrolone. Oxabolone is on the World Anti-Doping Agency's list of prohibited substances, and is therefore banned from use in most major sports. Oxabolone cypionate is a relatively rare drug that was once produced in Europe for human use. Was used for the treatment of osteoporosis. It is no longer produced by pharmaceutical companies; Upjohn and Pharmacia were the primary producers of it previously.

Serotonin (5-hydroxytryptamine, or 5-HT) is a monoamine neurotransmitter produced by serotonergic neurons in the CNS and enterochromaffin cells in the gastrointestinal tract. Pharmacologic action of serotonin is mediated by a large and diverse range of 5-HT receptors. Serotonin plays an important part in the biochemistry of depression, migraine, bipolar disorder, and anxiety. It is also believed to be influential on sexuality and appetite. Creatinine is a product of the metabolic breakdown of creatine phosphate in muscle. Creatinine is filtered by healthy kidneys. Serotonin creatinine sulfate complex was the first isolated salt form of serotonin.

Clorprenaline is a β2-adrenergic receptor agonist. As a bronchodilator it has been used for the treatment of bronchial asthma, bronchitis and other respiratory diseases. It is a potential new lean meat-boosting feed additive because it can promote animal muscular mass growth and decrease fat accumulation.

Avorelin is a superagonist of natural luteinizing-hormone-releasing-hormone. Avorelin has been formulated in high molecular weight polylactic glycolic acid to afford protracted and continuous release of the peptide from subcutaneous implants. Avorelin has been in phase II clinical trials by Mediolanum for the treatment of prostate cancer, breast cancer and endometriosis. However, this research has been discontinued. Adverse events mainly related to androgen suppression (hot flushes, decreased libido and impotence) or the nature of the disease (skeletal pain).